Literature DB >> 7575435

Induction of Ca2+/calmodulin-stimulated cyclic AMP phosphodiesterase (PDE1) activity in Chinese hamster ovary cells (CHO) by phorbol 12-myristate 13-acetate and by the selective overexpression of protein kinase C isoforms.

S Spence1, G Rena, G Sweeney, M D Houslay.   

Abstract

The cAMP phosphodiesterase (PDE) activity of CHO cells was unaffected by the addition of Ca2+ +calmodulin (CaM), indicating the absence of any PDE1 (Ca2+/CaM-stimulated PDE) activity. Treatment with the tumour promoting phorbol ester phorbol 12-myristate 13-acetate (PMA) led to the rapid transient induction of PDE1 activity which attained a maximum value after about 13 h before slowly decreasing. Such induction was attenuated by actinomycin D. PCR primers were designed to hybridize with two regions identified as being characteristic of PDE1 forms found in various species and predicted to amplify a 601 bp fragment. RT-PCR using degenerate primers allowed an approx. 600 bp fragment to be amplified from RNA preparations of rat brain but not from CHO cells unless they had been treated with PMA. CHO cells transfected to overexpress protein kinase C (PKC)-alpha and PKC-epsilon, but not those transfected to overexpress PKC-beta I or PKC-gamma, exhibited a twofold higher PDE activity. They also expressed a PDE1 activity, with Ca2+/CaM effecting a 1.8-2.8-fold increase in total PDE activity. RT-PCR, with PDE1-specific primers, identified an approx. 600 bp product in CHO cells transfected to overexpress PKC-alpha and PKC-epsilon, but not in those overexpressing PKC-beta I or PKC-gamma. Treatment of PKC-alpha transfected cells with PMA caused a rapid, albeit transient, increase in PDE1 activity, which reached a maximum some 1 h after PMA challenge, before returning to resting levels some 2 h later. The residual isobutylmethylxanthine (IBMX)-insensitive PDE activity was dramatically reduced (approx. 4-fold) in the PKC-gamma transfectants, suggesting that the activity of the cyclic AMP-specific IBMX-insensitive PDE7 activity was selectively reduced by overexpression of this particular PKC isoform. These data identify a novel point of 'cross-talk' between the lipid and cyclic AMP signalling systems where the action of specific PKC isoforms is shown to cause the induction of Ca2+/CaM-stimulated PDE (PDE1) activity. It is suggested that this protein kinase C-mediated process might involve regulation of PDE1 gene expression by the AP-1 (fos/jun) system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575435      PMCID: PMC1135991          DOI: 10.1042/bj3100975

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  63 in total

1.  Identification and characterization of both the cytosolic and particulate forms of cyclic GMP-stimulated cyclic AMP phosphodiesterase from rat liver.

Authors:  N J Pyne; M E Cooper; M D Houslay
Journal:  Biochem J       Date:  1986-03-01       Impact factor: 3.857

2.  The complete primary structure of protein kinase C--the major phorbol ester receptor.

Authors:  P J Parker; L Coussens; N Totty; L Rhee; S Young; E Chen; S Stabel; M D Waterfield; A Ullrich
Journal:  Science       Date:  1986-08-22       Impact factor: 47.728

3.  Metallothionein gene expression is regulated by serum factors and activators of protein kinase C.

Authors:  R J Imbra; M Karin
Journal:  Mol Cell Biol       Date:  1987-04       Impact factor: 4.272

4.  Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene.

Authors:  M E Greenberg; E B Ziff
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

5.  Resistance of a separated form of canine ureteral phosphodiesterase activity to inhibition by xanthines and papaverine.

Authors:  R M Weiss; J G Hardman; J N Wells
Journal:  Biochem Pharmacol       Date:  1981-08-15       Impact factor: 5.858

Review 6.  Cellular control through interactions between cyclic nucleotides and calcium.

Authors:  M J Berridge
Journal:  Adv Cyclic Nucleotide Protein Phosphorylation Res       Date:  1984

7.  A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes.

Authors:  R J Marchmont; M D Houslay
Journal:  Biochem J       Date:  1980-05-01       Impact factor: 3.857

8.  Isolation of multiple classes of mutants of CHO cells resistant to cyclic AMP.

Authors:  M M Gottesman; A LeCam; M Bukowski; I Pastan
Journal:  Somatic Cell Genet       Date:  1980-01

9.  Rous sarcoma virus transformed cells are resistant to cyclic AMP.

Authors:  C W Roth; T Singh; I Pastan; M M Gottesman
Journal:  J Cell Physiol       Date:  1982-04       Impact factor: 6.384

10.  The phorbol ester TPA inhibits cyclic AMP phosphodiesterase activity in intact hepatocytes.

Authors:  F Irvine; N J Pyne; M D Houslay
Journal:  FEBS Lett       Date:  1986-11-24       Impact factor: 4.124

View more
  10 in total

1.  Protein kinase C isoforms play differential roles in the regulation of adipocyte differentiation.

Authors:  I Fleming; S J MacKenzie; R G Vernon; N G Anderson; M D Houslay; E Kilgour
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

2.  Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca2+/calmodulin-stimulated cAMP phosphodiesterase.

Authors:  S Spence; G Rena; M Sullivan; S Erdogan; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

3.  Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.

Authors:  S J MacKenzie; M D Houslay
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

4.  Growth hormone and phorbol esters require specific protein kinase C isoforms to activate mitogen-activated protein kinases in 3T3-F442A cells.

Authors:  S MacKenzie; I Fleming; M D Houslay; N G Anderson; E Kilgour
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

5.  Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines.

Authors:  L Pooley; Y Shakur; G Rena; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

6.  Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.

Authors:  S Erdogan; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

7.  Gonadotropin-releasing hormone receptor concentration differentially regulates intracellular signaling pathways in GGH3 cells.

Authors:  J H Pinter; J A Janovick; P M Conn
Journal:  Pituitary       Date:  1999-11       Impact factor: 4.107

8.  Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells.

Authors:  X Jiang; J Li; M Paskind; P M Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

9.  Constitutive activation of the G-protein subunit Galphas within forebrain neurons causes PKA-dependent alterations in fear conditioning and cortical Arc mRNA expression.

Authors:  Michele P Kelly; York-Fong Cheung; Christopher Favilla; Steven J Siegel; Stephen J Kanes; Miles D Houslay; Ted Abel
Journal:  Learn Mem       Date:  2008-01-28       Impact factor: 2.460

10.  In vitro and in silico analysis of the effects of D2 receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations.

Authors:  Wilhelmus E A de Witte; Joost W Versfelt; Maria Kuzikov; Solene Rolland; Victoria Georgi; Philip Gribbon; Sheraz Gul; Dymphy Huntjens; Piet Hein van der Graaf; Meindert Danhof; Amaury Fernández-Montalván; Gesa Witt; Elizabeth C M de Lange
Journal:  Br J Pharmacol       Date:  2018-09-21       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.